TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30707179

Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 164

Group type: COMPARATOR
Intervention: Non-surgical controls
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All groups (1 year postoperatively)
Number of subjects: 164
Study: 28682972

Group type: EXPERIMENTAL
Intervention: Radiofrequency energy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 40
Study: 26000757

Group type: EXPERIMENTAL
Intervention: CBT-E
Number of subjects: 130

Group type: COMPARATOR
Intervention: IPT
Number of subjects: 130
Study: 23873561

Group type: EXPERIMENTAL
Intervention: Myo-inositol (MYO) supplementation
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Microbial phytase supplementation
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Myo-inositol and microbial phytase supplementation (simultaneously)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Diet with lower Ca and dP concentration
Number of subjects: 1200
Study: 21803850

Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide (FC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Fludarabine alone
Number of subjects: 278
Study: 19090549

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing EPA (33 patients)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (19 patients)
Number of subjects: 52
Study: 16982225

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 12573305

Group type: EXPERIMENTAL
Intervention: Postmenopausal patients with depression
Number of subjects: 35

Group type: COMPARATOR
Intervention: Postmenopausal controls
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Premenopausal patients with depression
Number of subjects: 35
Study: 10720131

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) alfa treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cytogenetic remission
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Complete cytogenetic remission
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Karyotype responses
Number of subjects: 71
Study: 8836226

Group type: EXPERIMENTAL
Intervention: Forward Walking (FW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Backward Walking (BW)
Number of subjects: 10
Study: 1413984

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (0; 1.12; 2.24; 3.37 g n-3 FA/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (3.37 g n-3 FA/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 3863197

Group type: EXPERIMENTAL
Intervention: 0.25 mg PGE2 triacetin gel administered twice over a 12 hour period
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5 mg PGE2 triacetin gel administered as a single dose
Number of subjects: 0
Study: 31994519

Group type: EXPERIMENTAL
Intervention: Rehabilitation program including psychopharmacological, psychotherapeutic and socio‐therapeutic procedures
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 128
Study: 29689122

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Group A)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (Group C)
Number of subjects: 161

Group type: COMPARATOR
Intervention: No treatment (Group B)
Number of subjects: 161
Study: 26459161

Group type: EXPERIMENTAL
Intervention: Rhubarb
Number of subjects: 94

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 94

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 94
Study: 25747752

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untrained (UT)
Number of subjects: 26
Study: 23733273

Group type: EXPERIMENTAL
Intervention: Integrated adventure-based training and health education program
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (received same amount of time and attention without specific effect)
Number of subjects: 71
Study: 21940729

Group type: EXPERIMENTAL
Intervention: Eplerenone therapy for 24 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 93
Study: 19423946

Group type: EXPERIMENTAL
Intervention: 1,800 mg of eicosapentaenoic acid (EPA) + statin
Number of subjects: 1050

Group type: COMPARATOR
Intervention: statin alone (control group)
Number of subjects: 1050
Study: 16977362

Group type: EXPERIMENTAL
Intervention: Aerosolized bovine-prepared fibrin glue
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no fibrin glue)
Number of subjects: 22
Study: 14628190

Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 1.25 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Zydis Selegiline 10 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Zydis Selegiline 5 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Conventional selegiline tablets 10 mg
Number of subjects: 197
Study: 10877128

Group type: EXPERIMENTAL
Intervention: Pustulosis palmoplantaris
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Generalized pustular psoriasis
Number of subjects: 12
Study: 9276109

Group type: EXPERIMENTAL
Intervention: Chronic Vagus Nerve Stimulation (VNS)
Number of subjects: 8
Study: 8061382

Group type: EXPERIMENTAL
Intervention: Triple-dose gadoteridol (0.3 mmol/kg total: 0.1 mmol/kg + 0.2 mmol/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Single-dose gadoteridol (0.1 mmol/kg)
Number of subjects: 9
Study: 3195807

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31741283

Group type: EXPERIMENTAL
Intervention: Preservative-free hydrocortisone 0.335% for 12 days four times daily followed by 2 days twice daily instillation (intense treatment group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preservative-free hydrocortisone 0.335% for 8 days three times daily followed by 3 days twice daily treatment (standard treatment group)
Number of subjects: 60
Study: 29871697

Group type: EXPERIMENTAL
Intervention: Arm cranking exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 28612179

Group type: EXPERIMENTAL
Intervention: CT-P10 1000 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: RTX 1000 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 154

Group type: COMPARATOR
Intervention: RTX
Number of subjects: 154
Study: 25527766

Group type: EXPERIMENTAL
Intervention: 4 whole-body UVB treatments with a total dose of 6 or 7.5 standard erythema doses during a 10-day period
Number of subjects: 92

Group type: COMPARATOR
Intervention: Vitamin D₃-fortified bread and milk
Number of subjects: 92
Study: 25458157

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg
Number of subjects: 0
Study: 22984466

Group type: EXPERIMENTAL
Intervention: Personalised normative feedback (PNF) provided by email
Number of subjects: 1751

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 1751

Group type: COMPARATOR
Intervention: Delayed measurement control group
Number of subjects: 1751
Study: 20307624

Group type: EXPERIMENTAL
Intervention: Moderate RDA toothpaste
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High RDA toothpaste
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low RDA toothpaste
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study: 18771373

Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg, every 12 hours for six doses
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control site (healthy gingiva)
Number of subjects: 8
Study: 15653658

Group type: EXPERIMENTAL
Intervention: (90)Y-DOTATOC (8.1-22.9 GBq)
Number of subjects: 18
Study: 12204968

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) 600 mg/day, Nelfinavir (NFV) 750 mg three times daily, Stavudine (d4T) 30 or 40 mg twice daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV), Nelfinavir (NFV), and Stavudine (d4T) therapy
Number of subjects: 18
Study: 9973070

Group type: EXPERIMENTAL
Intervention: Stratified randomization
Number of subjects: 0
Study: 9097333

Group type: EXPERIMENTAL
Intervention: Structured empowerment programme with a trained psychologist during 20 weekly 1-hour sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group passively attended by the psychologist during equal time conditions
Number of subjects: 0
Study: 8412364

Group type: EXPERIMENTAL
Intervention: Butyrate suppositories
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glutamine suppositories
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (conventional therapy for pouchitis discontinued)
Number of subjects: 19
Study: 3531373

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29409128

Group type: EXPERIMENTAL
Intervention: Project MOVE
Number of subjects: 72
Study: 27061338

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24398824

Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (XR) (50 to 300 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Amitriptyline (10 to 75 mg daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release (XR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 90
Study: 22349808

Group type: EXPERIMENTAL
Intervention: Amuvatinib DPC with high-fat meal
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Amuvatinib LSC (single-dose)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Amuvatinib LSC 300 mg every 8 h (multiple-dose)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 58
Study: 20297950

Group type: EXPERIMENTAL
Intervention: Fenofibrate (145 mg NanoCrystal tablet)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 18356266

Group type: EXPERIMENTAL
Intervention: Low-dose transpupillary thermotherapy (TTT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 98
Study: 15664306

Group type: EXPERIMENTAL
Intervention: Fish oil (8 g per day)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Olive oil (placebo, 8 g per day)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (Fish oil and Olive oil)
Number of subjects: 77
Study: 12452875

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream 3 days per week with occlusion
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream 3 days per week without occlusion
Number of subjects: 183
Study: 10328192

Group type: EXPERIMENTAL
Intervention: Topical sucralfate 4 times a day for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7585833

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g daily for 10 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8417865

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2 mg daily after placebo
Number of subjects: 32
Study: 3542091

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFL) 24 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prednisone (Pd) 20 mg/day
Number of subjects: 12
Study: 29053977

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDI Subjective Depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDRS Psychic Depression, BDI Subjective Depression, BDI Self-Blame
Number of subjects: 0
Study: 26024583

Group type: EXPERIMENTAL
Intervention: Antireflux biliary stent (group B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ordinary Tannenbaum stent (group A)
Number of subjects: 16
Study: 25237481

Group type: EXPERIMENTAL
Intervention: Community treatment orders (CTOs)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Community mental health teams' approach
Number of subjects: 333
Study: 22708645

Group type: EXPERIMENTAL
Intervention: Lamotrigine + placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Lamotrigine + placebo (BD I subgroup)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lamotrigine + divalproex ER
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lamotrigine + divalproex ER (BD I subgroup)
Number of subjects: 86
Study: 19842011

Group type: EXPERIMENTAL
Intervention: Modafinil (titrated up to a maximum of 400 mg/day over 4 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 13
Study: 18852316

Group type: EXPERIMENTAL
Intervention: Statistical natural language processing method for extracting trial participants
Number of subjects: 223

Group type: COMPARATOR
Intervention: Manual identification of trial participants
Number of subjects: 223
Study: 16022951

Group type: EXPERIMENTAL
Intervention: 10-microg dose in the 30-day release group
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 30-microg dose in the 30-day release group
Number of subjects: 244

Group type: COMPARATOR
Intervention: Bare metal Conor stent
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Eluting stent group
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: 30-day release groups (0% and 3.4%)
Number of subjects: 244
Study: 12459617

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using glass-ionomer
Number of subjects: 835
Study: 10091916

Group type: EXPERIMENTAL
Intervention: Mouth rinse A
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Mouth rinse B
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control mouth rinse
Number of subjects: 109
Study: 9550353

Group type: EXPERIMENTAL
Intervention: CDP-choline (500 mg daily for 10 days every six months)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CDP-choline plus one hour of occlusion daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: One hour of occlusion daily
Number of subjects: 45
Study: 1835334

Group type: EXPERIMENTAL
Intervention: Surgery plus two preoperative and three postoperative intralesional injections of triamcinolone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Surgery plus oral colchicine (1.2 mg per day) initiated 3 weeks after surgery and continued for 5 months
Number of subjects: 36
Study: 7027655

Group type: EXPERIMENTAL
Intervention: Topical Clobetasol-17-propionate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Other topical corticoids
Number of subjects: 90
Study: 30956265

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 28793974

Group type: EXPERIMENTAL
Intervention: GSK561679 (CRF1 receptor antagonist)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 25855926

Group type: EXPERIMENTAL
Intervention: Urinary kallidinogenase (0.15 PNAU/d, for 7 days) after rt‐PA (0.9 mg/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group received rt‐PA (0.9 mg/kg)
Number of subjects: 200
Study: 23835501

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 2784
Study: 22092206

Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (DL)
Number of subjects: 100
Study: 19461530

Group type: EXPERIMENTAL
Intervention: 7-Day Physical Activity Recall (7-Day PAR)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Accelerometer
Number of subjects: 139
Study: 17201542

Group type: EXPERIMENTAL
Intervention: Social exclusion manipulation (participants told they would end up alone or were rejected by others)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Social exclusion manipulation
Number of subjects: 7
Study: 15173773

Group type: EXPERIMENTAL
Intervention: Attenuation-corrected studies using a gender-independent normal database
Number of subjects: 95

Group type: COMPARATOR
Intervention: Conventional reconstruction and gender-specific database quantification
Number of subjects: 95
Study: 11703991

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptifibatide (0.75 dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eptifibatide (0.5 dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9743925

Group type: EXPERIMENTAL
Intervention: Heparin 2 U/ml saline flush solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Heparin 10 U/ml saline flush solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Saline flush solution
Number of subjects: 90
Study: 7818628

Group type: EXPERIMENTAL
Intervention: Bougie dilatation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Balloon dilatation
Number of subjects: 93
Study: 3337087

Group type: COMPARATOR
Intervention: First vaccination (first vac)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Two or more recent vaccinations (multivac)
Number of subjects: 3
Study: 31027051

Group type: EXPERIMENTAL
Intervention: Gelidium elegans (1g)
Number of subjects: 100
Study: 28306531

Group type: EXPERIMENTAL
Intervention: Micro-physiotherapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham micro-physiotherapy
Number of subjects: 61
Study: 25691237

Group type: EXPERIMENTAL
Intervention: Three‐minute video describing CPR and intubation plus verbal communication of participants' preferences to their physicians
Number of subjects: 150
Study: 23759263

Group type: EXPERIMENTAL
Intervention: 15 mg ALA-P plus 1.8 mg iron
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 21039672

Group type: EXPERIMENTAL
Intervention: Velusetrag 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Velusetrag 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Velusetrag 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18391135

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.50 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combination of naltrexone and ondansetron
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 16670166

Group type: EXPERIMENTAL
Intervention: T(4)‐T(3) combination therapy
Number of subjects: 1216
Study: 14581402

Group type: EXPERIMENTAL
Intervention: Exercise-induced periodic breathing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Severe HF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moderate HF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Periodic breathing, severe HF, and moderate HF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Periodic breathing
Number of subjects: 40
Study: 11093363

Group type: EXPERIMENTAL
Intervention: Iloperidone (8 mg/day to 32 mg/day)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Iloperidone (compared with haloperidol)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 3300
Study: 8818856

Group type: EXPERIMENTAL
Intervention: 3-day azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-day azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10-day roxithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: azithromycin
Number of subjects: 0
Study: 1433880

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with droperidol, fentanyl and ketamine (DFK)
Number of subjects: 36
Study: 2987601

Group type: EXPERIMENTAL
Intervention: 200 mg megestrol acetate (MA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 400 mg megestrol acetate (MA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 600 mg megestrol acetate (MA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 800 mg megestrol acetate (MA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) equivalent dosages 1000-1500 mg
Number of subjects: 33
Study: 31173362

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 577

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 577
Study: 30031803

Group type: EXPERIMENTAL
Intervention: Feedback Group (FG)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study: 26368836

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 55
Study: 24576857

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation (1200 mg·d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation
Number of subjects: 10
Study: 23114133

Group type: EXPERIMENTAL
Intervention: Newly diagnosed group (19 patients)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stable group (17 patients)
Number of subjects: 46
Study: 20195124

Group type: EXPERIMENTAL
Intervention: Electroacustimulation (ReliefBand) and pharmacologic measures
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standardized pharmacologic postoperative nausea and vomiting prevention
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Electroacustimulation (ReliefBand)
Number of subjects: 122
Study: 18076534

Group type: EXPERIMENTAL
Intervention: Antidepressant (AD) treatment
Number of subjects: 123

Group type: COMPARATOR
Intervention: No Antidepressant (non-users)
Number of subjects: 123
Study: 16789520

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 60
Study: 12625847

Group type: EXPERIMENTAL
Intervention: Sildenafil (PDE5 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrates
Number of subjects: 0